Business Wire09.22.20
Tandem Diabetes Care Inc., a leading insulin delivery and diabetes technology company, has appointed Peyton Howell as an independent member of its Board of Directors. Howell brings to the Tandem board extensive reimbursement, health insurance, and patient access experience across a broad range of disease states in the hospital, physician, pharmacy and home care settings.
“Peyton brings significant expertise to our Board, drawing on more than 25 years of healthcare and leadership experience,” said John Sheridan, president and CEO. “Her appointment reflects our commitment to ensuring that we have a broad mix of skills and perspectives on Tandem’s board, and we are confident she will provide valuable insight from across the healthcare landscape as we continue to execute our strategy to lead in insulin therapy management.”
Howell is currently the chief commercial and strategy officer at Parexel International, a global clinical research organization servicing the life sciences industry. Prior to joining Parexel, Howell held a wide range of senior leadership positions at AmerisourceBergen, including leading Global Sourcing and Manufacturer Relations and advancing specialty and biotech products and solutions for physicians, health systems and specialty pharmacies. She was a founder and president of Lash Group, a patient support services company, and an early pioneer of programs to support patient access, reimbursement, and adherence to new therapies including services related to diabetes, such as patient assistance and reimbursement support for continuous glucose monitors. Howell was president of Lash Group for nearly a decade following its acquisition by AmerisourceBergen.
Howell is a recognized national speaker on health policy, patient access and reimbursement issues. She has served as director of the AmerisourceBergen Foundation, the National Association of Chain Drug Stores Foundation, and the Healthcare Distribution Alliance Foundation.
Howell earned a bachelor of arts degree in speech communication from The University of Illinois, Champaign and a master’s degree in health administration from The Ohio State University.
“Peyton brings significant expertise to our Board, drawing on more than 25 years of healthcare and leadership experience,” said John Sheridan, president and CEO. “Her appointment reflects our commitment to ensuring that we have a broad mix of skills and perspectives on Tandem’s board, and we are confident she will provide valuable insight from across the healthcare landscape as we continue to execute our strategy to lead in insulin therapy management.”
Howell is currently the chief commercial and strategy officer at Parexel International, a global clinical research organization servicing the life sciences industry. Prior to joining Parexel, Howell held a wide range of senior leadership positions at AmerisourceBergen, including leading Global Sourcing and Manufacturer Relations and advancing specialty and biotech products and solutions for physicians, health systems and specialty pharmacies. She was a founder and president of Lash Group, a patient support services company, and an early pioneer of programs to support patient access, reimbursement, and adherence to new therapies including services related to diabetes, such as patient assistance and reimbursement support for continuous glucose monitors. Howell was president of Lash Group for nearly a decade following its acquisition by AmerisourceBergen.
Howell is a recognized national speaker on health policy, patient access and reimbursement issues. She has served as director of the AmerisourceBergen Foundation, the National Association of Chain Drug Stores Foundation, and the Healthcare Distribution Alliance Foundation.
Howell earned a bachelor of arts degree in speech communication from The University of Illinois, Champaign and a master’s degree in health administration from The Ohio State University.
